Our ability to provide valuable solutions and products for human health depends on our strong team of scientists and R&D and production systems that can meet the needs.
We have always maintained close scientific research cooperation with scientific research institutions and institutions of higher learning, such as the Institute of Medical Biotechnology - Chinese Academy of Medical Sciences, National Institutes of Health (NIH), Harbin Medical University, Peking University Health Science Center, Shanghai Institute for Biological Sciences, East China University of Science and Technology, Shenyang Pharmaceutical University, etc. so that every product research and development can get the attention and support of scientists from beginning to end.
We have strong independent research and development capabilities. Tonglian Pharmaceutical Research Institute and Shanghai Tonglian Pharmaceutical Technology Co., Ltd., two pharmaceutical research and development institutions, are responsible for synthesis, fermentation, extraction, and new drug research and development, with nearly 100 professionals in pharmacy, pharmaceutical analysis, Pharmacology, pharmaceutical engineering, biopharmaceuticals, clinical medicine, and other medical and pharmaceutical-related fields, forming a complete research and development system from laboratory research, pilot test to industrialization. Shenyang Tonglian Institute of Life Sciences, which is under construction, has a key research center of anti-infective drugs, pharmaceutical research center, medical research center, environmental protection center, the administrative center, and pilot base. Our goal is to build an international R&D and cooperation platform based on this. On this platform, independent R&D, technology introduction, and cooperative development can be carried out, and a whole chain of project establishment, preclinical research, clinical research, and registration application can be formed.
Based on strong scientific research strength and excellent R&D system, we have completed the development of China's Class I new drug Carrimycin and its preparation, China's Class II new drug Rifaximin, and China's Class VI generic drug Moxifloxacin hydrochloride and its preparation, as well as the technology transfer of China's Class II new drug Butyl flufenamate and its preparation, as well as the supplemental application for existing products. China's Class I new drugs, Carrimycin API, and preparations, and China's Class II new drugs, Butyl flufenamate, and Rifaximin API and preparations, have been approved by the National Medical Products Administration (NMPA).